Koninklijke Philips N.V.

PHGNYSEUSD

THESIS ALERT

Email me when the PHG thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$30.20
−$0.21 (−0.69%)Today 1M +25.45%
After hours$30.200.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$30.41
Prior regular-session close from the quote source.
$29.81–$30.30
Regular-session low and high so far today.
1.8M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$23.62–$33.44
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own PHG if the company sustains recent margin improvement (driven by higher gross margins and cost actions), converts that operating recovery into repeatable free cash flow, and avoids new large product‑liability or regulatory charges that would wipe.

PHG price history

Latest price$30.20Today−$0.21 (-0.69%)
PHG +22.49%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Sustained operating‑income improvements will result from permanent gross‑margin expansion and structural cost reductions, not just one‑time benefits or the end of prior charges.StrengtheningMateriality: High

    operating_income improved from -1529000000.0 EUR (FY2022) to -115000000.0 EUR (FY2023) to 529000000.0 EUR (FY2024) to 1424000000.0 EUR (FY2025). If true, Philips will convert flat revenue into rising operating profit and cash; if false, a reversal will quickly push earnings back into losses and erode valuation.

    Watch: Discovery of a new large product‑liability or regulatory exposure requiring a multihundred‑million to billion‑euro charge.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_income improved from -1529000000.0 EUR (FY2022) to -115000000.0 EUR (FY2023) to 529000000.0 EUR (FY2024) to 1424000000.0 EUR (FY2025).

    Open source ↗
  • Revenue growth will need to shift from the current roughly flat base to positive organic growth via market share gains or new product adoption for valuation expansion; otherwise margin gains alone may cap upside.HoldingMateriality: High

    revenue has been roughly stable: 17156000000.0 EUR (FY2021), 17827000000.0 EUR (FY2022), 18169000000.0 EUR (FY2023), 18021000000.0 EUR (FY2024), 17834000000.0 EUR (FY2025). Margins can improve valuation, but sustained shareholder returns typically require both margin durability and top‑line growth; without revenue acceleration upside is limited to de‑risking and multiple re‑rating.

    Watch: Secular volume declines in core markets or hospitals delaying capital spending.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    revenue has been roughly stable: 17156000000.0 EUR (FY2021), 17827000000.0 EUR (FY2022), 18169000000.0 EUR (FY2023), 18021000000.0 EUR (FY2024), 17834000000.0 EUR (FY2025).

    Open source ↗
  • The company is building a cash buffer that can absorb legacy liabilities or fund strategic options without immediate distress.StrengtheningMateriality: Medium

    cash and cash equivalents rose from 1172000000.0 EUR (FY2022) to 1869000000.0 EUR (FY2023) to 2401000000.0 EUR (FY2024) to 2794000000.0 EUR (FY2025). Adequate cash reduces existential risk from settlements/charges and gives management flexibility for investment or returns; loss of that buffer would materially increase downside.

    Watch: A large, unexpected settlement or remediation expense that exceeds the current cash buffer or forces new debt.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    cash and cash equivalents rose from 1172000000.0 EUR (FY2022) to 1869000000.0 EUR (FY2023) to 2401000000.0 EUR (FY2024) to 2794000000.0 EUR.

    Open source ↗
  • Reported net income will remain positive only if no new material one‑off charges (recalls, regulatory penalties, large warranty provisions) materialize going forward.HoldingMateriality: Medium

    net_income swung from -1605000000.0 EUR (FY2022) and -698000000.0 EUR (FY2024) to 897000000.0 EUR (FY2025). Net income is the clearest proof investors care about; a new large charge would reverse the FY2025 recovery and damage credibility and valuation.

    Watch: Regulators or courts require multi‑hundred‑million to billion‑euro remediation or settlement costs.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    net_income swung from -1605000000.0 EUR (FY2022) and -698000000.0 EUR (FY2024) to 897000000.0 EUR (FY2025).

    Open source ↗
  • The trend in shareholders' equity will reveal whether recovery is being driven by profitable operations or offset by asset write‑downs/dividends/buybacks; destructive capital allocation while litigation risk exists would degrade intrinsic value.HoldingMateriality: Medium

    equity decreased from 13283000000.0 EUR (FY2022) to 12061000000.0 EUR (FY2023) to 12043000000.0 EUR (FY2024) to 10990000000.0 EUR (FY2025). If equity decline is due to write‑downs or large returns of capital before contingencies are settled, owners bear outsized risk; prudent allocation preserves optionality.

    Watch: Management announces large share repurchases or special dividends while major contingency reserves remain unresolved.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    equity decreased from 13283000000.0 EUR (FY2022) to 12061000000.0 EUR (FY2023) to 12043000000.0 EUR (FY2024) to 10990000000.0 EUR (FY2025).

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Sustained operating‑income improvements will result from permanent gross‑margin expansion and structural cost reductions, not just one‑time benefits or the end of prior charges. If true, Philips will convert flat revenue into rising operating profit and cash; if false, a reversal will quickly push earnings back into losses and erode valuation.

Revenue growth will need to shift from the current roughly flat base to positive organic growth via market share gains or new product adoption for valuation expansion; otherwise margin gains alone may cap upside. Margins can improve valuation, but sustained shareholder returns typically require both margin durability and top‑line growth; without revenue acceleration upside is limited to de‑risking and multiple re‑rating.

The company is building a cash buffer that can absorb legacy liabilities or fund strategic options without immediate distress. Adequate cash reduces existential risk from settlements/charges and gives management flexibility for investment or returns; loss of that buffer would materially increase downside.

Reported net income will remain positive only if no new material one‑off charges (recalls, regulatory penalties, large warranty provisions) materialize going forward. Net income is the clearest proof investors care about; a new large charge would reverse the FY2025 recovery and damage credibility and valuation.

The trend in shareholders' equity will reveal whether recovery is being driven by profitable operations or offset by asset write‑downs/dividends/buybacks; destructive capital allocation while litigation risk exists would degrade intrinsic value. If equity decline is due to write‑downs or large returns of capital before contingencies are settled, owners bear outsized risk; prudent allocation preserves optionality.

All standing thesis claims
Original report summary

the company sustains recent margin improvement (driven by higher gross margins and cost actions), converts that operating recovery into repeatable free cash flow, and avoids new large product‑liability or regulatory charges that would wipe.

Evidence assessed Nov 6, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Koninklijke Philips Nv

Where the evidence on Koninklijke Philips Nv stands: Holding on the latest evidence (Nov 6, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.

Bull case: what the evidence supports

  • Sustained operating‑income improvements will result from permanent gross‑margin expansion and structural cost reductions, not just one‑time benefits or the end of prior charges.

    sec.gov ↗

  • Revenue growth will need to shift from the current roughly flat base to positive organic growth via market share gains or new product adoption for valuation expansion; otherwise margin gains alone may cap upside.

    sec.gov ↗

  • The company is building a cash buffer that can absorb legacy liabilities or fund strategic options without immediate distress.

    sec.gov ↗

  • Reported net income will remain positive only if no new material one‑off charges (recalls, regulatory penalties, large warranty provisions) materialize going forward.

    sec.gov ↗

  • The trend in shareholders' equity will reveal whether recovery is being driven by profitable operations or offset by asset write‑downs/dividends/buybacks; destructive capital allocation while litigation risk exists would degrade intrinsic value.

    sec.gov ↗

Bear case: what would count against it

  • Discovery of a new large product‑liability or regulatory exposure requiring a multihundred‑million to billion‑euro charge.

    sec.gov ↗

  • Secular volume declines in core markets or hospitals delaying capital spending.

    sec.gov ↗

  • A large, unexpected settlement or remediation expense that exceeds the current cash buffer or forces new debt.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Koninklijke Philips Nv

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Koninklijke Philips Nv’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Foreign issuer material report (6-K).

    Koninklijke Philips Nv filed an SEC report on 2026-11-03: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  2. Mixed
    Foreign issuer material report (6-K).

    Koninklijke Philips Nv filed an SEC report on 2026-07-28: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  3. Mixed
    Foreign issuer material report (6-K).

    Koninklijke Philips Nv filed an SEC report on 2026-06-02: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Discovery of a new large product‑liability or regulatory exposure requiring a multihundred‑million to billion‑euro charge.
  • Secular volume declines in core markets or hospitals delaying capital spending.
  • A large, unexpected settlement or remediation expense that exceeds the current cash buffer or forces new debt.
  • Regulators or courts require multi‑hundred‑million to billion‑euro remediation or settlement costs.
  • Management announces large share repurchases or special dividends while major contingency reserves remain unresolved.

PHG news

Loading headlines…

Financial statements

PHG income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

PHG: quick answers

What is PHG's short interest?
As of October 30, 2026, 2.1M PHG shares were sold short, down 25.6% from the count before. At the stock's average daily volume that is 1.7 days to cover. FINRA publishes the count twice a month. PHG short interest history
Have members of Congress traded PHG?
26 trades in PHG have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed PHG trade
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.